Esperion Therapeutics (ESPR) EPS (Weighted Average and Diluted) (2019 - 2025)
Historic EPS (Weighted Average and Diluted) for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to -$0.16.
- Esperion Therapeutics' EPS (Weighted Average and Diluted) fell 666.67% to -$0.16 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.54, marking a year-over-year increase of 1562.5%. This contributed to the annual value of -$0.03 for FY2024, which is 9872.39% up from last year.
- Esperion Therapeutics' EPS (Weighted Average and Diluted) amounted to -$0.16 in Q3 2025, which was down 666.67% from -$0.06 recorded in Q2 2025.
- Over the past 5 years, Esperion Therapeutics' EPS (Weighted Average and Diluted) peaked at $0.34 during Q1 2024, and registered a low of -$3.5 during Q1 2021.
- For the 5-year period, Esperion Therapeutics' EPS (Weighted Average and Diluted) averaged around -$0.87, with its median value being -$0.5 (2023).
- In the last 5 years, Esperion Therapeutics' EPS (Weighted Average and Diluted) surged by 14303.8% in 2024 and then plummeted by 16176.47% in 2025.
- Esperion Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$2.39 in 2021, then surged by 69.03% to -$0.74 in 2022, then surged by 32.43% to -$0.5 in 2023, then surged by 77.73% to -$0.11 in 2024, then plummeted by 43.7% to -$0.16 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.16 for Q3 2025, versus -$0.06 for Q2 2025 and -$0.21 for Q1 2025.